Testa Analytical to showcase its OEM design and manufacture capabilities at Analytica 2020

Testa Analytical to showcase its OEM design and manufacture capabilities at Analytica 2020

Testa Analytical's new small volume electrode pushes the boundaries of Zeta Potential measurement Backed by decades of experience, Testa Analytical has created, for a growing number of leading international laboratory and process instrument companies, fully optimized high-performance GPC/SEC detectors, GPC/SEC Pumps, accessories and software products customizable to meet their exact needs. Visitors to Analytica Booth A2-429 will be able to meet Testa Analytical's team of knowledgeable technical and engineering staff to discuss your product development needs and to learn how they can provide seamless integration of their proprietary technology into your existing or new product. Also, on display will be a full range of state-of-the-art scientific instruments that use scattered light to measure zeta potential, particle size, and molecular weight. Testa Analytical are dedicated to supplying the most accurate, reliable, and easy-to-use particle characterization instruments on the market. Our modular instrument design allows us to fully customize every aspect of our products, ensuring that our customers receive precisely what they need to meet their research goals. The Testa Analytical commitment to its customers continues long after a sale is made. Our knowledgeable team of technical staff is standing by to assist you with your toughest application challenges. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More